BioGeometry
China · Biotech · AI
BioGeometry develops generative AI models and experimental workflows for protein design, drug discovery and enzyme engineering.
Designing proteins for medicine and industry
BioGeometry helps researchers design and improve biological molecules. Its work spans antibodies for drug development and enzymes used in synthetic biology, connecting computational design with experimental testing.
GeoFlow models biomolecular sequence, structure and function within a generative AI framework. Researchers can use it to explore new protein designs and optimize candidates, while high-throughput laboratory workflows test how those designs perform.
From models to biological products
The company develops both its modelling platform and proprietary biological programmes. Its biomedical work includes antibody design and optimization; its synthetic biology work targets more efficient production processes and industrial enzymes. BioGeometry operates from Beijing with an R&D centre in Shanghai.
Funding history
4 rounds · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A+ | Undisclosed | China Life Capital — LeadFortune Capital — ParticipantGuofang Chuangtou — ParticipantGuokai Kechuang — ParticipantReal Power Capital — ParticipantShanghai Biomedical Innovation and Translation Fund — Participant | |
| Strategic financing | Undisclosed | CAS Investment — LeadFortune Capital — LeadLINK-X CAPITAL — LeadShanghai Biomedical Innovation and Translation Fund — LeadGaorong Ventures — ParticipantIndex AI Industry Innovation Fund — Participant | |
| Pre-A | Undisclosed | Jiangmen Ventures — LeadGaorong Ventures — ParticipantSJ Jiacheng — ParticipantZhipu AI — Participant | |
| Angel round | Undisclosed | Gaorong Ventures — Participant |